|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Li X, Zhao L, Chen C, Nie J and Jiao B:
Can EGFR be a therapeutic target in breast cancer? Biochim Biophys
Acta Rev Cancer. 1877:1887892022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Levantini E, Maroni G, Del Re M and Tenen
DG: EGFR signaling pathway as therapeutic target in human cancers.
Semin Cancer Biol. 85:253–275. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roskoski R Jr: Small molecule inhibitors
targeting the EGFR/ErbB family of protein-tyrosine kinases in human
cancers. Pharmacol Res. 139:395–411. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duarte HO, Reis CA and Gomes J: Insights
on ErbB glycosylation-contributions to precision oncology. Trends
Cancer. 8:448–455. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lucas LM, Dwivedi V, Senfeld JI, Cullum
RL, Mill CP, Piazza JT, Bryant IN, Cook LJ, Miller ST, Lott JHt, et
al: The Yin and Yang of ERBB4: Tumor suppressor and oncoprotein.
Pharmacol Rev. 74:18–47. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maramotti S, Paci M, Manzotti G, Rapicetta
C, Gugnoni M, Galeone C, Cesario A and Lococo F: Soluble epidermal
growth gactor receptors (sEGFRs) in cancer: Biological aspects and
clinical relevance. Int J Mol Sci. 17:5932016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hart V, Gautrey H, Kirby J and
Tyson-Capper A: HER2 splice variants in breast cancer:
Investigating their impact on diagnosis and treatment outcomes.
Oncotarget. 11:4338–4357. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park EJ and Lee CW: Soluble receptors in
cancer: Mechanisms, clinical significance, and therapeutic
strategies. Exp Mol Med. 56:100–109. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cohen S: Origins of growth factors: NGF
and EGF. J Biol Chem. 283:33793–33797. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reiter JL, Threadgill DW, Eley GD, Strunk
KE, Danielsen AJ, Sinclair CS, Pearsall RS, Green PJ, Yee D,
Lampland AL, et al: Comparative genomic sequence analysis and
isolation of human and mouse alternative EGFR transcripts encoding
truncated receptor isoforms. Genomics. 71:1–20. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Banys-Paluchowski M, Witzel I, Riethdorf
S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B,
Kasimir-Bauer S, Pantel K, et al: Evaluation of serum epidermal
growth factor receptor (EGFR) in correlation to circulating tumor
cells in patients with metastatic breast cancer. Sci Rep.
7:173072017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hsu JL and Hung MC: The role of HER2,
EGFR, and other receptor tyrosine kinases in breast cancer. Cancer
Metast Rev. 35:575–588. 2016. View Article : Google Scholar
|
|
14
|
de Araujo RA, da Luz FAC, da Costa Marinho
E, Nascimento CP, de Andrade Marques L, Delfino PFR, Antonioli RM,
Araujo BJ, da Silva A, Dos Reis Monteiro MLG, et al: Epidermal
growth factor receptor (EGFR) expression in the serum of patients
with triple-negative breast carcinoma: Prognostic value of this
biomarker. Ecancermedicalscience. 16:14312022.PubMed/NCBI
|
|
15
|
Lin CR, Chen WS, Kruiger W, Stolarsky LS,
Weber W, Evans RM, Verma IM, Gill GN and Rosenfeld MG: Expression
cloning of human EGF receptor complementary DNA: Gene amplification
and three related messenger RNA products in A431 cells. Science.
224:843–848. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Merlino GT, Xu YH, Ishii S, Clark AJ,
Semba K, Toyoshima K, Yamamoto T and Pastan I: Amplification and
enhanced expression of the epidermal growth factor receptor gene in
A431 human carcinoma cells. Science. 224:417–419. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ullrich A, Coussens L, Hayflick JS, Dull
TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J,
et al: Human epidermal growth factor receptor cDNA sequence and
aberrant expression of the amplified gene in A431 epidermoid
carcinoma cells. Nature. 309:418–425. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu YH, Richert N, Ito S, Merlino GT and
Pastan I: Characterization of epidermal growth factor receptor gene
expression in malignant and normal human cell lines. Proc Natl Acad
Sci USA. 81:7308–7312. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Merlino GT, Ishii S, Whang-Peng J, Knutsen
T, Xu YH, Clark AJ, Stratton RH, Wilson RK, Ma DP, Roe BA, et al:
Structure and localization of genes encoding aberrant and normal
epidermal growth factor receptor RNAs from A431 human carcinoma
cells. Mol Cell Biol. 5:1722–1734. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Filmus J, Pollak MN, Cailleau R and Buick
RN: MDA-468, a human breast cancer cell line with a high number of
epidermal growth factor (EGF) receptors, has an amplified EGF
receptor gene and is growth inhibited by EGF. Biochem Biophys Res
Commun. 128:898–905. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Negron-Vega L, Cora EM, Perez-Torres M,
Tang SC, Maihle NJ and Ryu JS: Expression of EGFR isoform D is
regulated by HER receptor activators in breast cancer cells.
Biochem Biophys Rep. 31:1013262022.PubMed/NCBI
|
|
22
|
Mayes EL and Waterfield MD: Biosynthesis
of the epidermal growth factor receptor in A431 cells. EMBO J.
3:531–537. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Perez-Torres M, Valle BL, Maihle NJ,
Negron-Vega L, Nieves-Alicea R and Cora EM: Shedding of epidermal
growth factor receptor is a regulated process that occurs with
overexpression in malignant cells. Exp Cell Res. 314:2907–2918.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wilken JA, Perez-Torres M, Nieves-Alicea
R, Cora EM, Christensen TA, Baron AT and Maihle NJ: Shedding of
soluble epidermal growth factor receptor (sEGFR) is mediated by a
metalloprotease/fibronectin/integrin axis and inhibited by
cetuximab. Biochemistry. 52:4531–4540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sanderson MP, Keller S, Alonso A, Riedle
S, Dempsey PJ and Altevogt P: Generation of novel, secreted
epidermal growth factor receptor (EGFR/ErbB1) isoforms via
metalloprotease-dependent ectodomain shedding and exosome
secretion. J Cell Biochem. 103:1783–1797. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Basu A, Raghunath M, Bishayee S and Das M:
Inhibition of tyrosine kinase activity of the epidermal growth
factor (EGF) receptor by a truncated receptor form that binds to
EGF: Role for interreceptor interaction in kinase regulation. Mol
Cell Biol. 9:671–677. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lim SO, Li CW, Xia W, Lee HH, Chang SS,
Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, et al: EGFR signaling
enhances aerobic glycolysis in triple-negative breast cancer cells
to promote tumor growth and immune escape. Cancer Res.
76:1284–1296. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tamam M, Ozcevik H, Kulduk G, Acar Tayyar
MN and Babacan GB: Evaluating the correlation between pretreatment
(18)F-FDG PET/CT metabolic parameters and tumor-infiltrating
lymphocyte levels in nonluminal breast cancer and impact on
survival. Pathol Oncol Res. 30:16120142024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Y, Zhu M, Zhu J, Xu F and Chen Y:
Nanoproteomics deciphers the prognostic value of EGFR family
proteins-based liquid biopsy. Anal Biochem. 671:1151332023.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wignarajah S, Chianella I and Tothill IE:
Development of ectrochemical immunosensors for HER-1 and HER-2
analysis in serum for breast cancer patients. Biosensors (Basel).
13:3552023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hudelist G, Kostler WJ,
Gschwantler-Kaulich D, Czerwenka K, Kubista E, Muller R, Helmy S,
Manavi M, Zielinski CC and Singer CF: Serum EGFR levels and
efficacy of trastuzumab-based therapy in patients with metastatic
breast cancer. Eur J Cancer. 42:186–192. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Witzel I, Thomssen C, Krenkel S, Wilczak
W, Bubenheim M, Pantel K, Neumann R, Jänicke F and Müller V:
Clinical utility of determination of HER-2/neu and EGFR fragments
in serum of patients with metastatic breast cancer. Int J Biol
Markers. 21:131–140. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lafky JM, Baron AT, Cora EM, Hillman DW,
Suman VJ, Perez EA, Ingle JN and Maihle NJ: Serum soluble epidermal
growth factor receptor concentrations decrease in postmenopausal
metastatic breast cancer patients treated with letrozole. Cancer
Res. 65:3059–3062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sandri MT, Johansson HA, Zorzino L,
Salvatici M, Passerini R, Maisonneuve P, Rocca A, Peruzzotti G and
Colleoni M: Serum EGFR and serum HER-2/neu are useful predictive
and prognostic markers in metastatic breast cancer patients treated
with metronomic chemotherapy. Cancer. 110:509–517. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Souder C, Leitzel K, Ali SM, Demers L,
Evans DB, Chaudri-Ross HA, Hackl W, Hamer P, Carney W and Lipton A:
Serum epidermal growth factor receptor/HER-2 predicts poor survival
in patients with metastatic breast cancer. Cancer. 107:2337–2345.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kjaer IM, Olsen DA, Brandslund I, Bechmann
T, Jakobsen EH, Bogh SB and Madsen JS: Dysregulated EGFR pathway in
serum in early-stage breast cancer patients: A case control study.
Sci Rep. 10:67142020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Müller V, Witzel I, Pantel K, Krenkel S,
Lück HJ, Neumann R, Keller T, Dittmer J, Jänicke F and Thomssen C:
Prognostic and predictive impact of soluble epidermal growth factor
receptor (sEGFR) protein in the serum of patients treated with
chemotherapy for metastatic breast cancer. Anticancer Res.
26:1479–1487. 2006.PubMed/NCBI
|
|
38
|
Rocca A, Cancello G, Bagnardi V, Sandri
MT, Torrisi R, Zorzino L, Viale G, Pietri E, Veronesi P,
Dellapasqua S, et al: Perioperative serum VEGF and extracellular
domains of EGFR and HER2 in early breast cancer. Anticancer Res.
29:5111–5119. 2009.PubMed/NCBI
|
|
39
|
Kjaer IM, Olsen DA, Brandslund I, Bechmann
T, Jakobsen EH, Bogh SB and Madsen JS: Prognostic impact of serum
levels of EGFR and EGFR ligands in early-stage breast cancer. Sci
Rep. 10:165582020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kjaer IM, Bechmann T, Brandslund I and
Madsen JS: Prognostic and predictive value of EGFR and EGFR-ligands
in blood of breast cancer patients: A systematic review. Clin Chem
Lab Med. 56:688–701. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schippinger W, Dandachi N, Regitnig P,
Hofmann G, Balic M, Neumann R, Samonigg H and Bauernhofer T: The
predictive value of EGFR and HER-2/neu in tumor tissue and serum
for response to anthracycline-based neoadjuvant chemotherapy of
breast cancer. Am J Clin Pathol. 128:630–637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schechter AL, Stern DF, Vaidyanathan L,
Decker SJ, Drebin JA, Greene MI and Weinberg RA: The neu oncogene:
An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature.
312:513–516. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Coussens L, Yang-Feng TL, Liao YC, Chen E,
Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J,
Francke U, et al: Tyrosine kinase receptor with extensive homology
to EGF receptor shares chromosomal location with neu oncogene.
Science. 230:1132–1139. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Semba K, Kamata N, Toyoshima K and
Yamamoto T: A v-erbB-related protooncogene, c-erbB-2, is distinct
from the c-erbB-1/epidermal growth factor-receptor gene and is
amplified in a human salivary gland adenocarcinoma. Proc Natl Acad
Sci USA. 82:6497–6501. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fukushige S, Matsubara K, Yoshida M,
Sasaki M, Suzuki T, Semba K, Toyoshima K and Yamamoto T:
Localization of a novel v-erbB-related gene, c-erbB-2, on human
chromosome 17 and its amplification in a gastric cancer cell line.
Mol Cell Biol. 6:955–958. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schechter AL, Hung MC, Vaidyanathan L,
Weinberg RA, Yang-Feng TL, Francke U, Ullrich A and Coussens L: The
neu gene: An erbB-homologous gene distinct from and unlinked to the
gene encoding the EGF receptor. Science. 229:976–978. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cheng X: A comprehensive review of HER2 in
cancer biology and therapeutics. Genes (Basel). 15:9032024.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wolff AC, Hammond MEH, Allison KH, Harvey
BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P,
Hanna W, et al: Human epidermal growth factor receptor 2 testing in
breast cancer: American Society of Clinical Oncology/College of
American Pathologists Clinical Practice Guideline Focused Update. J
Clin Oncol. 36:2105–2122. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
National Cancer Institute (NIH), .
Surveillance, Epidemiology, and End Results Program. Cancer Stat
Facts: Female Breast Cancer Subtypes. National Cancer Institute;
Rockville, MD: 2025, https://seer.cancer.gov/statfacts/html/breast-subtypes.html
|
|
50
|
Wu Y, Li L, Zhang D and Ma F: Prognostic
value of the serum HER2 extracellular domain level in breast
cancer: A systematic review and meta-analysis. Cancers (Basel).
14:45512022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Doherty JK, Bond C, Jardim A, Adelman JP
and Clinton GM: The HER-2/neu receptor tyrosine kinase gene encodes
a secreted autoinhibitor. Proc Natl Acad Sci USA. 96:10869–10874.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Silipo M, Gautrey H, Satam S, Lennard T
and Tyson-Capper A: How is Herstatin, a tumor suppressor splice
variant of the oncogene HER2, regulated? RNA Biol. 14:536–543.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Aigner A, Juhl H, Malerczyk C, Tkybusch A,
Benz CC and Czubayko F: Expression of a truncated 100 kDa HER2
splice variant acts as an endogenous inhibitor of tumour cell
proliferation. Oncogene. 20:2101–2111. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Scott GK, Robles R, Park JW, Montgomery
PA, Daniel J, Holmes WE, Lee J, Keller GA, Li WL, Fendly BM, et al:
A truncated intracellular HER2/neu receptor produced by alternative
RNA processing affects growth of human carcinoma cells. Mol Cell
Biol. 13:2247–2257. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gautrey H, Jackson C, Dittrich AL, Browell
D, Lennard T and Tyson-Capper A: SRSF3 and hnRNP H1 regulate a
splicing hotspot of HER2 in breast cancer cells. RNA Biol.
12:1139–1151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hart V, Silipo M, Satam S, Gautrey H,
Kirby J and Tyson-Capper A: HER2-PI9 and HER2-I12: Two novel and
functionally active splice variants of the oncogene HER2 in breast
cancer. J Cancer Res Clin Oncol. 147:2893–2912. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wan J, Sazani P and Kole R: Modification
of HER2 pre-mRNA alternative splicing and its effects on breast
cancer cells. Int J Cancer. 124:772–777. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liu PC, Liu X, Li Y, Covington M, Wynn R,
Huber R, Hillman M, Yang G, Ellis D, Marando C, et al:
Identification of ADAM10 as a major source of HER2 ectodomain
sheddase activity in HER2 overexpressing breast cancer cells.
Cancer Biol Ther. 5:657–664. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zabrecky JR, Lam T, McKenzie SJ and Carney
W: The extracellular domain of p185/neu is released from the
surface of human breast carcinoma cells, SK-BR-3. J Biol Chem.
266:1716–1720. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Carney WP, Neumann R, Lipton A, Leitzel K,
Ali S and Price CP: Potential clinical utility of serum HER-2/neu
oncoprotein concentrations in patients with breast cancer. Clin
Chem. 49:1579–1598. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zheng H, Zhong A, Xie S, Wang Y, Sun J,
Zhang J, Tong Y, Chen M, Zhang G, Ma Q, et al: Elevated serum HER-2
predicts poor prognosis in breast cancer and is correlated to
ADAM10 expression. Cancer Med. 8:679–685. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen LM and Chai KX: Proteolytic cleavages
in the extracellular domain of receptor tyrosine kinases by
membrane-associated serine proteases. Oncotarget. 8:56490–56505.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Vazquez-Martin A, Oliveras-Ferraros C,
Cufí S, Del Barco S, Martin-Castillo B and Menendez JA: Lapatinib,
a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage
of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer
cell growth. J Cell Physiol. 226:52–57. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zhang X, Chen J, Weng Z, Li Q, Zhao L, Yu
N, Deng L, Xu W, Yang Y, Zhu Z, et al: A new anti-HER2 antibody
that enhances the anti-tumor efficacy of trastuzumab and pertuzumab
with a distinct mechanism of action. Mol Immunol. 119:48–58. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Perrier A, Gligorov J, Lefèvre G and
Boissan M: The extracellular domain of Her2 in serum as a biomarker
of breast cancer. Lab Invest. 98:696–707. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Hu P, Feng J, Zhou T, Wang J, Jing B, Yu
M, Hu M, Zhang X, Shen B and Guo N: In vivo identification of the
interaction site of ErbB2 extracellular domain with its
autoinhibitor. J Cell Physiol. 205:335–343. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Hu P, Zhou T, Qian L, Wang J, Shi M, Yu M,
Yang Y, Zhang X, Shen B and Guo N: Sequestering ErbB2 in
endoplasmic reticulum by its autoinhibitor from translocation to
cell surface: An autoinhibition mechanism of ErbB2 expression.
Biochem Biophys Res Commun. 342:19–27. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Shamieh LS, Evans AJ, Denton MC and
Clinton GM: Receptor binding specificities of Herstatin and its
intron 8-encoded domain. FEBS Lett. 568:163–166. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lv M, Qiao C, Jiang N, Li X, Yu M, Hou C,
Li Y, Feng J and Shen B: The peptide derived from erbB2
auto-inhibitor herstatin shared in the same epitope and function
with functional antibody 2C4. Mol Biotechnol. 51:174–182. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Tashiro D, Suetaka S, Sato N, Ooka K,
Kunihara T, Kudo H, Inatomi J, Hayashi Y and Arai M: Intron-encoded
domain of Herstatin, an autoinhibitor of human epidermal growth
factor receptors, is intrinsically disordered. Front Mol Biosci.
9:8629102022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Azios NG, Romero FJ, Denton MC, Doherty JK
and Clinton GM: Expression of herstatin, an autoinhibitor of
HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks
EGF activation of the EGF receptor. Oncogene. 20:5199–5209. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Jhabvala-Romero F, Evans A, Guo S, Denton
M and Clinton GM: Herstatin inhibits heregulin-mediated breast
cancer cell growth and overcomes tamoxifen resistance in breast
cancer cells that overexpress HER-2. Oncogene. 22:8178–8186. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Justman QA and Clinton GM: Herstatin, an
autoinhibitor of the human epidermal growth factor receptor 2
tyrosine kinase, modulates epidermal growth factor signaling
pathways resulting in growth arrest. J Biol Chem. 277:20618–20624.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Koletsa T, Kostopoulos I, Charalambous E,
Christoforidou B, Nenopoulou E and Kotoula V: A splice variant of
HER2 corresponding to Herstatin is expressed in the noncancerous
breast and in breast carcinomas. Neoplasia. 10:687–696. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Gebhardt F, Zänker KS and Brandt B:
Differential expression of alternatively spliced c-erbB-2 mRNA in
primary tumors, lymph node metastases, and bone marrow
micrometastases from breast cancer patients. Biochem Biophys Res
Commun. 247:319–323. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Ghedini GC, Ciravolo V, Tortoreto M,
Giuffrè S, Bianchi F, Campiglio M, Mortarino M, Figini M, Coliva A,
Carcangiu ML, et al: Shed HER2 extracellular domain in
HER2-mediated tumor growth and in trastuzumab susceptibility. J
Cell Physiol. 225:256–265. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Antos A, Topolska-Woś A, Woś M, Mitura A,
Sarzyńska P, Lipiński T, Kurylcio A, Ziółkowski P, Świtalska M,
Tkaczuk-Włach J, et al: The unique monoclonal antibodies and
immunochemical assay for comprehensive determination of the
cell-bound and soluble HER2 in different biological samples. Sci
Rep. 14:39782024. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Ahirwar R: Recent advances in
nanomaterials-based electrochemical immunosensors and aptasensors
for HER2 assessment in breast cancer. Mikrochim Acta. 188:3172021.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Chen X, Su C, Yang Y, Weng Z, Zhuang Q,
Hong G, Peng H and Chen W: Clinical evaluation of the HER2
extracellular domain in breast cancer patients by
Herceptin-encapsulated gold nanocluster probe-based
electrochemiluminescence immunoassay. Anal Chem. 97:872–879. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ma X, Cheng H, Hou J, Jia Z, Wu G, Lü X,
Li H, Zheng X and Chen C: Detection of breast cancer based on novel
porous silicon Bragg reflector surface-enhanced Raman
spectroscopy-active structure. Chinese Optics Letters.
18:0517012020. View Article : Google Scholar
|
|
81
|
Zeng Q, Chen C, Chen C, Song H, Li M, Yan
J and Lv X: Serum Raman spectroscopy combined with convolutional
neural network for rapid diagnosis of HER2-positive and
triple-negative breast cancer. Spectrochim Acta A Mol Biomol
Spectrosc. 286:1220002023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Shao H, Feng C, Wang Z, Zhu S and Zheng X:
The expression and prognostic significance of Topo-II and c-erbB-2
in breast cancer. Minerva Med. 115:458–464. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Wang S, Chen Y, Li W, Hao C, Zhang L, Zhao
W, Shi Y and Tong Z: Serum HER2 level predicts therapeutic efficacy
and prognosis in advanced breast cancer patients. Breast Cancer
(Dove Med Press). 16:163–179. 2024.PubMed/NCBI
|
|
84
|
Qui S, Takeshita T, Sueta A, Tomiguchi M,
Goto-Yamaguchi L, Hidaka K, Suzu I, Yamamoto Y and Iwase H:
Analysis of plasma HER2 copy number in cell-free DNA of breast
cancer patients: A comparison with HER2 extracellular domain
protein level in serum. Breast Cancer. 28:746–754. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Eppenberger-Castori S, Klingbiel D,
Ruhstaller T, Dietrich D, Rufle DA, Rothgiesser K, Pagani O and
Thürlimann B: Plasma HER2ECD a promising test for patient prognosis
and prediction of response in HER2 positive breast cancer: Results
of a randomized study-SAKK 22/99. BMC Cancer. 20:1142020.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Fabricio ASC, Michilin S, Zancan M,
Agnolon V, Peloso L, Dittadi R, Scapinello A, Ceccarelli C and Gion
M: Shed HER2 surrogacy evaluation in primary breast cancer
patients: A study assessing tumor tissue HER2 expression at both
extracellular and intracellular levels. Scan J Clin Lab Invest.
79:260–267. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Pokhrel R, Yadav BK, Sharma N, Sharma VK,
Tuladhar ET, Raut M, Bhattarai A, Dubey RK, Niraula A, Mishra A, et
al: Comparison of Her2/Neu oncoprotein in serum and tissue samples
in women withbreast cancer. Asian Pac J Cancer Prev. 23:429–433.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zhang P, Xiao J, Ruan Y, Zhang Z and Zhang
X: Monitoring value of serum HER2 as a predictive biomarker in
patients with metastatic breast cancer. Cancer Manag Res.
12:4667–4675. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Perrier A, Boelle PY, Chrétien Y, Gligorov
J, Lotz JP, Brault D, Comperat E, Lefèvre G and Boissan M: An
updated evaluation of serum sHER2, CA15.3, and CEA levels as
biomarkers for the response of patients with metastatic breast
cancer to trastuzumab-based therapies. PLoS One. 15:e02273562020.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Giordani E, Allegretti M, Sinibaldi A,
Michelotti F, Ferretti G, Ricciardi E, Ziccheddu G, Valenti F, Di
Martino S, Ercolani C, et al: Monitoring changing patterns in HER2
addiction by liquid biopsy in advanced breast cancer patients. J
Exp Clin Cancer Res. 43:1822024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Lee SB, Lee JW, Yu JH, Ko BS, Kim HJ, Son
BH, Gong G, Lee HJ, Kim SB, Jung KH, et al: Preoperative serum HER2
extracellular domain levels in primary invasive breast cancer. BMC
Cancer. 14:9292014. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Todorović-Raković N, Milovanović J,
Radulovic M and Greenman J: Serum HER2 as potential prognostic
biomarker in primary breast cancer patients. Growth Factors.
43:37–44. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Reix N, Malina C, Chenard MP, Bellocq JP,
Delpous S, Molière S, Sevrin A, Neuberger K, Tomasetto C and
Mathelin C: A prospective study to assess the clinical utility of
serum HER2 extracellular domain in breast cancer with HER2
overexpression. Breast Cancer Res Treat. 160:249–259. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Zhang Z, Li C, Fan H, Xiang Q, Xu L, Liu
Q, Zhou S, Xie Q, Chen S, Mu G, et al: Prognostic value of baseline
serum HER2 extracellular domain level with a cut-off value of 15
ng/ml in patients with breast cancer: A systematic review and
meta-analysis. Breast Cancer Res Treat. 172:513–521. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Kadooh QA, Al-Ziaydi AG and Hamza AJ:
Evaluation of the influence of trastuzumab therapy on serum levels
of HER-2 protein and breast cancer cell lines. Prz Menopauzalny.
23:57–63. 2024.PubMed/NCBI
|
|
96
|
Köstler WJ, Schwab B, Singer CF, Neumann
R, Rücklinger E, Brodowicz T, Tomek S, Niedermayr M, Hejna M,
Steger GG, et al: Monitoring of serum Her-2/neu predicts response
and progression-free survival to trastuzumab-based treatment in
patients with metastatic breast cancer. Clin Cancer Res.
10:1618–1624. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wang X, Xiong M, Shao Z, Xiu B, Zhang Q,
Liu D, Chi W, Zhang L, Chen M, Ren H, et al: Assessing neoadjuvant
treatment response through serum human epidermal growth factor
receptor 2 (HER2) dynamics. Gland Surg. 14:207–218. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Lam L, McAndrew N, Yee M, Fu T, Tchou JC
and Zhang H: Challenges in the clinical utility of the serum test
for HER2 ECD. Biochim Biophys Acta. 1826:199–208. 2012.PubMed/NCBI
|
|
99
|
Di Gioia D, Dresse M, Mayr D, Nagel D,
Heinemann V and Stieber P: Serum HER2 in combination with CA 15-3
as a parameter for prognosis in patients with early breast cancer.
Clin Chim Acta. 440:16–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Darlix A, Lamy PJ, Lopez-Crapez E,
Braccini AL, Firmin N, Romieu G, Thézenas S and Jacot W: Serum NSE,
MMP-9 and HER2 extracellular domain are associated with brain
metastases in metastatic breast cancer patients: Predictive
biomarkers for brain metastases? Int J Cancer. 139:2299–2311. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Banys-Paluchowski M, Witzel I, Riethdorf
S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B,
Kasimir-Bauer S, Pantel K, et al: Clinical relevance of serum HER2
and circulating tumor cell detection in metastatic breast cancer
patients. Anticancer Res. 37:3117–3128. 2017.PubMed/NCBI
|
|
102
|
Aurilio G, Sandri MT, Pruneri G, Zorzino
L, Botteri E, Munzone E, Adamoli L, Facchi G, Cullura D, Verri E,
et al: Serum HER2 extracellular domain levels and HER2 circulating
tumor cell status in patients with metastatic breast cancer. Future
Oncol. 12:2001–2008. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Dickinson K, Sharma A, Agnihotram RV,
Altuntur S, Park M, Meterissian S and Burnier JV: Circulating tumor
DNA and survival in metastatic breast cancer: A systematic review
and meta-analysis. JAMA Netw Open. 7:e24317222024. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Shen H, Liu M, Yang W, Xiao D, Peng Z, Rao
D and Huang D: Exosomal proteins: New targets for early diagnosis
and treatment of cancer. Front Immunol. 16:16134942025. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Kraus MH, Issing W, Miki T, Popescu NC and
Aaronson SA: Isolation and characterization of ERBB3, a third
member of the ERBB/epidermal growth factor receptor family:
Evidence for overexpression in a subset of human mammary tumors.
Proc Natl Acad Sci USA. 86:9193–9197. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Da Silva L, Simpson PT, Smart CE,
Cocciardi S, Waddell N, Lane A, Morrison BJ, Vargas AC, Healey S,
Beesley J, et al: HER3 and downstream pathways are involved in
colonization of brain metastases from breast cancer. Breast Cancer
Res. 12:R462010. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Zhu M, Yu M, Meng Y, Yang J, Wang X, Li L,
Liang Y and Kong F: HER3 receptor and its role in the therapeutic
management of metastatic breast cancer. J Transl Med. 22:6652024.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Katoh M, Yazaki Y, Sugimura T and Terada
M: c-erbB3 gene encodes secreted as well as transmembrane receptor
tyrosine kinase. Biochem Biophys Res Commun. 192:1189–1197. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Lee H and Maihle NJ: Isolation and
characterization of four alternate c-erbB3 transcripts expressed in
ovarian carcinoma-derived cell lines and normal human tissues.
Oncogene. 16:3243–3252. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Lee H, Akita RW, Sliwkowski MX and Maihle
NJ: A naturally occurring secreted human ErbB3 receptor isoform
inhibits heregulin-stimulated activation of ErbB2, ErbB3, and
ErbB4. Cancer Res. 61:4467–4473. 2001.PubMed/NCBI
|
|
111
|
Takahashi M, Hasegawa Y, Ikeda Y, Wada Y,
Tajiri M, Ariki S, Takamiya R, Nishitani C, Araki M, Yamaguchi Y,
et al: Suppression of heregulin β signaling by the single N-glycan
deletion mutant of soluble ErbB3 protein. J Biol Chem.
288:32910–32921. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Takamiya R, Takahashi M, Uehara Y, Ariki
S, Hashimoto J, Hasegawa Y and Kuroki Y: The single N-glycan
deletion mutant of soluble ErbB3 protein attenuates heregulin
β1-induced tumor progression by blocking of the HIF-1 and Nrf2
pathway. Biochem Biophys Res Commun. 454:364–368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Caviglia GP, Abate ML, Rolle E, Carucci P,
Armandi A, Rosso C, Olivero A, Ribaldone DG, Tandoi F, Saracco GM,
et al: The clinical role of serum epidermal growth factor receptor
3 in hepatitis C virus-infected patients with early hepatocellular
carcinoma. Biology (Basel). 10:2152021.PubMed/NCBI
|
|
114
|
D'Abronzo LS, Pan CX and Ghosh PM:
Evaluation of protein levels of the receptor tyrosine kinase ErbB3
in serum. Methods Mol Biol. 1655:319–334. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Plowman GD, Culouscou JM, Whitney GS,
Green JM, Carlton GW, Foy L, Neubauer MG and Shoyab M:
Ligand-specific activation of HER4/p180erbB4, a fourth member of
the epidermal growth factor receptor family. Proc Natl Acad Sci
USA. 90:1746–1750. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
El-Gamal MI, Mewafi NH, Abdelmotteleb NE,
Emara MA, Tarazi H, Sbenati RM, Madkour MM, Zaraei SO, Shahin AI
and Anbar HS: A review of HER4 (ErbB4) kinase, its impact on
cancer, and its inhibitors. Molecules. 26:73762021. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Elenius K, Corfas G, Paul S, Choi CJ, Rio
C, Plowman GD and Klagsbrun M: A novel juxtamembrane domain isoform
of HER4/ErbB4. Isoform-specific tissue distribution and
differential processing in response to phorbol ester. J Biol Chem.
272:26761–26768. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Elenius K, Choi CJ, Paul S, Santiestevan
E, Nishi E and Klagsbrun M: Characterization of a naturally
occurring ErbB4 isoform that does not bind or activate phosphatidyl
inositol 3-kinase. Oncogene. 18:2607–2615. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Sawyer C, Hiles I, Page M, Crompton M and
Dean C: Two erbB-4 transcripts are expressed in normal breast and
in most breast cancers. Oncogene. 17:919–924. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Segers VFM, Dugaucquier L, Feyen E,
Shakeri H and De Keulenaer GW: The role of ErbB4 in cancer. Cell
Oncol (Dordr). 43:335–352. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Hollmén M, Liu P, Kurppa K, Wildiers H,
Reinvall I, Vandorpe T, Smeets A, Deraedt K, Vahlberg T, Joensuu H,
et al: Proteolytic processing of ErbB4 in breast cancer. PLoS One.
7:e394132012. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Rio C, Buxbaum JD, Peschon JJ and Corfas
G: Tumor necrosis factor-alpha-converting enzyme is required for
cleavage of erbB4/HER4. J Biol Chem. 275:10379–10387. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Vecchi M, Baulida J and Carpenter G:
Selective cleavage of the heregulin receptor ErbB-4 by protein
kinase C activation. J Biol Chem. 271:18989–18995. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Brockhoff G: ‘Shedding’ light on HER4
signaling in normal and malignant breast tissues. Cell Signal.
97:1104012022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Olsen DA, Ostergaard B, Bokmand S, Wamberg
PA, Jakobsen EH, Jakobsen A and Brandslund I: HER1-4 protein
concentrations in normal breast tissue from breast cancer patients
are expressed by the same profile as in the malignant tissue. Clin
Chem Lab Med. 47:977–984. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Yuan CX, Lasut AL, Wynn R, Neff NT, Hollis
GF, Ramaker ML, Rupar MJ, Liu P and Meade R: Purification of Her-2
extracellular domain and identification of its cleavage site.
Protein Expr Purif. 29:217–222. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Li X, Xiang J, Wang J, Li J, Wu FX and Li
M: FUNMarker: Fusion network-based method to identify prognostic
and heterogeneous breast cancer biomarkers. IEEE/ACM Trans Comput
Biol Bioinform. 18:2483–2491. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Yi Leong HJ, Tan HD, Yap WH, Yin Chia AY,
Zacchigna S and Tang YQ: Identification of potentially therapeutic
target genes in metastatic breast cancer via integrative network
analysis. EJMO. 7:371–387. 2023. View Article : Google Scholar
|
